Cancer Research News 19 November 2025

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio Inc. (NYSE: NUVB) has quietly morphed from an obscure penny stock into one of 2025’s wildest oncology stories. As of December 11, 2025, the stock is trading in the high single digits (around $7.8–$8.0), up roughly 200% year‑to‑date,

11 December 2025

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly

10 December 2025

Business News · Cancer Research · NYSE:PFE · Obesity Treatments · Pharmaceuticals · Stock Market

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price

10 December 2025

Cancer Research · FDA Approvals · Investment Analysis · NYSE:GSK · Pharmaceuticals · Stock Market

Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Key Takeaways Below, we’ll walk through what happened to Johnson & Johnson stock after the bell on December 9 and what investors should watch before the U.S. market opens on Wednesday, December 10, 2025. 1. How Johnson & Johnson Stock

10 December 2025

Cancer Research · Dividends · Health News · Investment Tips · NYSE:JNJ · Stock Market

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Published: December 6, 2025 – For information only, not investment advice. Johnson & Johnson stock (NYSE: JNJ) is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings

6 December 2025

Cancer Research · Investment Analysis · Legal News · NYSE:JNJ · Pharmaceuticals · Stock Market

Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength – December 1, 2025

As of December 1, 2025. This article is for information only and is not investment advice. JNJ stock today: riding near record highs after a huge 2025 rally Johnson & Johnson (NYSE: JNJ) stock is trading close to its 52‑week

1 December 2025

Cancer Research · Dividend Stocks · Investment News · NYSE:JNJ · Pharma Industry · Stock Market

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Inc. (NYSE: PFE) spent Wednesday trading slightly lower despite a stream of fresh headlines that cut both ways for sentiment. The stock hovered around $25.7, giving back a fraction of Tuesday’s nearly 2% gain, as investors weighed upbeat news

26 November 2025

Cancer Research · Legal Issues · NYSE:PFE · Obesity · Pharmaceuticals · Stocks

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Published: November 23, 2025 Pfizer Inc. (NYSE: PFE) heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the

23 November 2025

Business News · Cancer Research · Dividends · Investing · Pharmaceuticals

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion

20 November 2025

Cancer Research · Healthcare · Medical Technology · Mergers & Acquisitions · NASDAQ:EXAS · NYSE:ABT · Stock Market News

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal

20 November 2025

Business News · Cancer Research · Healthcare · Medical Technology · Mergers & Acquisitions · NASDAQ:EXAS · NYSE:ABT

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025

Abbott Laboratories is in advanced talks to acquire cancer diagnostics specialist Exact Sciences, in what could be the healthcare giant’s largest deal in nearly a decade and a major shake-up for the global cancer testing market. Bloomberg+1 Abbott in Talks

19 November 2025

Cancer Research · Healthcare · Medical Technology · Mergers & Acquisitions · Stock Market

KZIA Stock News Today: Kazia Therapeutics Soars on Rare Cancer Response as Nasdaq Delisting Risk Looms

Kazia Therapeutics Limited (NASDAQ: KZIA) is back on traders’ radars today after unveiling a rare immune‑complete response in a patient with metastatic triple‑negative breast cancer (TNBC) – even as the micro‑cap oncology company discloses a fresh Nasdaq delisting warning and

19 November 2025

Biotech Stocks · Cancer Research · Investment Trends · Nasdaq News · Stock Market

Cancer Research News 19 November 2025 - 11 December 2025